Charcot-Marie-Tooth Disease
0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
NeurogeneNY - New York
1 programA Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
NMD PharmaNMD670
NeurogeneA Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)
Clinical Trials (2)
Total enrollment: 102 patients across 2 trials
Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
Start: Sep 2024Est. completion: Nov 202581 patients
Phase 2Completed
A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)
Start: Jul 2019Est. completion: Feb 202221 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.